Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 44 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 5% Imiquimod cream Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC

NCT03370406
View directory record Official record
Conditions
Carcinoma, Squamous Cell
Interventions
5-fluorouracil, Calcipotriene
Drug
Lead sponsor
Melissa Pugliano-Mauro
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Early Phase 1 Interventional

Topical Vitamin C for Treatment of Basal Cell Cancer

NCT04279535
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Topical Ascorbic Acid
Drug
Lead sponsor
Center for Biomedical Research, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Results available

Bioequivalence Study of Two Imiquimod Cream 5%

NCT00828568
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod 5% manufactured by Taro, Aldara - Imiquimod 5%, Imiquimod Vehicle manufactured by Taro
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Gilbert, Arizona • Tempe, Arizona • Tuscon, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 6, 2026, 2:05 PM EDT
Terminated Phase 1 Interventional

Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer

NCT03982004
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Epicutaneous cryoimmunotherapy, Topical imiquimod, Pembrolizumab, Dermatologic Quality of Life Index, Functional Assessment of Cancer Therapy, Intra-lesional GM-CSF, Cry-AC, Cutaneous tumor biopsy, Peripheral blood draw for research
Device · Drug · Other + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1

NCT00865644
View directory record Official record
Conditions
Neurofibromatosis Type 1, Cutaneous Neurofibromas
Interventions
Imiquimod 5% Cream
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

NCT03180684
View directory record Official record
Conditions
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN), VIN2, VIN3, Pre-cancerous Lesions of the Vulva, Human Papillomavirus (HPV)
Interventions
VGX-3100, Imiquimod 5% Cream, CELLECTRA™ 2000
Biological · Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Newark, Delaware • Augusta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Early Phase 1 Interventional Results available

Neoadjuvant Imiquimod Immunotherapy for Oral Cancer

NCT04883645
View directory record Official record
Conditions
Oral Squamous Cell Carcinoma
Interventions
Imiquimod 5% Cream
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands

NCT00115154
View directory record Official record
Conditions
Keratosis
Interventions
Aldara (imiquimod) cream, 5%
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
18
States / cities
Tucson, Arizona • Vista, California • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2007 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Phase 4 Interventional Results available

Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis

NCT00116649
View directory record Official record
Conditions
Keratosis
Interventions
imiquimod cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
32
States / cities
Phoenix, Arizona • Encino, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2010 · Synced Oct 6, 2026, 2:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

1-Year Follow up to the 1473-IMIQ Study

NCT00114023
View directory record Official record
Conditions
Keratosis
Interventions
Imiquimod 5% cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2007 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma

NCT01264731
View directory record Official record
Conditions
Melanoma
Interventions
MELITAC 12.1, Imiquimod
Biological · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

NCT02482428
View directory record Official record
Conditions
External Genital Warts
Interventions
Investigational Treatment, Aldara
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 6, 2026, 2:05 PM EDT
Terminated Phase 1 Interventional

Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma

NCT01400672
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
Tumor Lysate Vaccine, Imiquimod, Radiation therapy
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
3 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Phase 4 Interventional Results available

Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses

NCT00774787
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod 5% cream
Drug
Lead sponsor
Rigel Dermatology
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
St. Petersburg, Florida • Henderson, Nevada • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor

NCT01171469
View directory record Official record
Conditions
Brain Tumor, Glioblastoma, Medulloblastoma, Ependymoma, Anaplastic Astrocytoma
Interventions
Dendritic Cells, Imiquimod
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Phase 4 Interventional

Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia

NCT06840470
View directory record Official record
Conditions
Sebaceous Hyperplasia
Interventions
Imiquimod 5% Topical Cream
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Not applicable Interventional Results available

Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna

NCT00707174
View directory record Official record
Conditions
Cancer, Lentigo Maligna
Interventions
Imiquimod Cream, Tazarotene Cream 0.1%
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Not applicable Interventional Results available

Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks

NCT00585247
View directory record Official record
Conditions
Port Wine Stain
Interventions
Imiquimod, Placebo
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 With or Without Topical Aldara in Healthy Adults

NCT03472976
View directory record Official record
Conditions
Avian Influenza, Influenza Immunisation
Interventions
Aqueous Cream B.P., Imiquimod, Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04
Other · Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 6, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

NCT00273910
View directory record Official record
Conditions
High-Risk Melanoma
Interventions
gp100:209-217 (210M), Montanide ISA-51, Imiquimod
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2012 · Synced Oct 6, 2026, 2:05 PM EDT